Trimethoprim 100 mg + Polymyxine Sulphate B 1000 000 units
Fam Dorps
KetorolacTromethamine 5 mg/1ml
Ciprofox eye drops
Ciprofloxacine 3 mg/ml
Betoma Eye Drops
Betaxolol Hydrochloride 0.5 gm/100 ml + Benzalkonium Chloride 0.01 gm/100 ml
EYE PREPARATIONS
Generic Name
Active Ingredients
Ciprofox eye drops
Ciprofloxacine 3 mg/ml
Fam eye drops
KetorolacTromethamine 5 mg/1ml
RESPIRATORY SYSTEM
Generic Name
Active Ingredients
Philobaxine Tablets
Prenoxdiazine HCl 100 mg
Philobaxine Suspension
Prenoxdiazine 50 mg/5ml
HORMONES
Generic Name
Active Ingredients
Progesterone Capsule
Progesterone 100 mg
Levotroxine Capsule
L. Thyroxine Sodium unhydrous 0.1 mg
Production Vision
Our mission is to manufacture, develop and market primary care medicines that improve quality for patients and to make sure that these products are available to patients at affordable prices.
We do so through maintaining the highest professionals and ethical standards, implementing effective processes for identifying compounds and optimizing our drug development activities to bring the best drugs to market.
ACAPI delivers innovative and valuable products to protect human health by advancing pioneering science across the landscape of biotechnology, we provide effective medicines to fight disease in important areas of medical need, in ACAPI we have a world dedicated to research and development of health care products, ACAPI will continue to enhance its product line as well as its reputation among physicians, pharmacists and other health care products.
Composition Each tablet contains: Tofisopam 50 mg.
Pharmacological Actions
Tofisopam belongs to Homophthalazines (formerly called 2,3-benzodiazepines). It has been shown by in vitro receptor displacement studies that homophthalazines do not compete for dopamine receptors, serotonin receptors or binding sites of diazepam or GABA. The binding site of homophthalazines differ from the 1,4-benzodiazepine receptor binding sites.
Tofisopam, during clinical trials, exhibited an effective anxiolytic action and a characteristic psycho-autonomic stabilizing effect. It is therefore, can be considered as a “Harmonizing Tranquillizer”.
It has no sedative, muscle relaxant or an anticonvulsant effects. It does not impair, in fact it may even improve, the psychomotor and intellectual functions. No abuse or dependence develops during its usage. Therefore, it is safely discontinued without fear of withdrawal effects whatsoever.
Contrary to the cardiodepressive effect of other benzodiazepine derivatives, Tofisopam has an important coronary dilator effect. Besides its use as a tranquillizer, it may be of therapeutic value as anti-angina adjuvant as well.
Due to the lack of any central muscle relaxant action, No deprine can be successfully used in patients with myasthenia gravis, myopathy, neuropathic muscular atrophy.
Pharmacokinetics Tofisopam is well absorbed from the stomach and duodenum and reaches a maximum concentration in the blood in 1 to 1.5 hours following its oral administration. In chronic treatment no signs of accumulation were seen. Tofisopam passes through enterohepatic circulation and its metabolites are mainly excreted in faeces.
Indications
No deprine is indicated to relief autonomic manifestations of anxiety such as: 1- Cardio-vascular manifestations: Tachycardia, palpitations, systolic hypertension and psychogenic cardiac pain (cardiac neurosis). 2- Gastro-intestinal manifestations: Difficulty in swallowing, heart burn, vomiting and diarrhea, abdominal distension, indigestion, constipation and anorexia. 3- Psychological and nervous manifestations: Headache, tremors, hyper-reflexia and hyper-activity, “pains allover” secondary to muscular spasm. 4- Sexual manifestations: Impotence, pre-mature ejaculation and frigidity. 5- Skin manifestations: Alopecia, vitiligo, rashes, urticaria, eczema, neurodermatitis, itching, .. etc. 6- Gynaecological manifestations: Dysmenorrhoea, premenstrual tension and climacteric syndrome. 7- Urinary manifestations: Frequency of micturition and incontinence. 8- Respiratory manifestations: Sighing, dyspnea, tightness in chest, hyperventilation that may lead to respiratory alkalosis resulting sometimes in tetany and numbness in the extremities.
No deprine is indicated as adjuvant in “Psycho-somatic Disorders” such as: Coronary artery disease, cardiac arrhythmias, hypertension, peptic ulcer, ulcerative colitis, IBS, bronchial asthma, …. etc.
Side Effects Rare and include: Temporary gastrointestinal complaints, itching and exanthema. When exanthema appears, treatment should be discontinued.
Usage in Pregnancy Teratogenic effects have not been recorded so far, nevertheless, in the first three months of pregnancy, the use of Tofisopam is not recommended.
Dosage One tablet two to three times daily according to the case and the physician's directions.
Package Boxes, each contains two strips. Each strip contains ten tablets.
Manufactured by ALPHA-CHEM Advanced Pharmaceutical Industries S.A.E (ACAPI) Badr City, Third Industrial Zone, Cairo, EGYPT
